ライフサイエンスコーパス: chemoprophylaxis

1 cal patients who benefit from peri-operative chemoprophylaxis.

2 VTE and/or bleeding events with and without chemoprophylaxis.

3 Both agents are effective for chemoprophylaxis.

4 ficant VTE risk reduction after surgery with chemoprophylaxis.

5 t likely secondary to the longer duration of chemoprophylaxis.

6 carinii pneumonia is high despite widespread chemoprophylaxis.

7 linically relevant bleeding with and without chemoprophylaxis.

8 t have a significant VTE risk reduction with chemoprophylaxis.

9 ce alone is neither superior nor inferior to chemoprophylaxis.

10 zinc supplementation, a bed net, and malaria chemoprophylaxis.

11 established guidelines for postdischarge VTE chemoprophylaxis.

12 ted that these patients be discharged on VTE chemoprophylaxis.

13 circumcision, behavioral interventions, and chemoprophylaxis.

14 linicians need data on the safety of malaria chemoprophylaxis.

15 cluding class cancellations, quarantine, and chemoprophylaxis.

16 occus to identify candidates for intrapartum chemoprophylaxis.

17 using fourth-generation fluoroquinolones as chemoprophylaxis.

18 f whom had a history of receiving nevirapine chemoprophylaxis.

19 contacts, including 6001 (79%) who initiated chemoprophylaxis, 3642 (61%) who later completed treatme

20 ous studies have suggested the usefulness of chemoprophylaxis administered to close contacts of case-

21 d during long-term stays: discontinuation of chemoprophylaxis after the initial period, sequential re

22 M could help establish proof of concept that chemoprophylaxis against dengue is feasible.

23 ative (iPrEx), a global trial of preexposure chemoprophylaxis against human immunodeficiency virus ty

24 The increasing use of successful chemoprophylaxis against many important HIV-associated i

25 vaquone-proguanil provides effective malaria chemoprophylaxis against P. falciparum challenge at dosi

26 etroviral therapy may be able to discontinue chemoprophylaxis against Pneumocystis carinii pneumonia

27 mal changes in fecal flora, and more liberal chemoprophylaxis against this disease should be consider

28 illness in travelers, but current first-line chemoprophylaxis agents do not prevent relapses of vivax

29 Aspirin chemoprophylaxis alone cannot be considered a substitute

30 use of intermittent pneumatic compression or chemoprophylaxis alone to a combination of both treatmen

31 It is shown that chemoprophylaxis always reduces the basic reproduction n

32 Renewed research regarding the use of chemoprophylaxis among family members of cholera cases m

33 nalysis to investigate benefits and harms of chemoprophylaxis among surgical patients individually ri

34 I, including 22 of 6001 (0.4%) who initiated chemoprophylaxis and 24 of 1596 (1.5%) who did not initi

35 ve strategies for the selection of women for chemoprophylaxis and for the management of infants are d

36 There was variable use of antiviral chemoprophylaxis and screening of recipients for H1N1 in

37 s during prophylactic chloroquine treatment (chemoprophylaxis and sporozoites (CPS)).

38 ing chloroquine chemoprophylaxis (hereafter, chemoprophylaxis and sporozoites [CPS] immunization) ind

39 chemoprophylaxis) and pregnancy (chloroquine chemoprophylaxis and sulfadoxine-pyrimethamine intermitt

40 opment of new classes of antiviral drugs for chemoprophylaxis and treatment, which are urgently neede

41 einforce existing recommendations to provide chemoprophylaxis and vaccination against major preventab

42 ormidable challenge for developing effective chemoprophylaxis and vaccine approaches.

43 rmed H5N1-infected poultry without antiviral chemoprophylaxis and with minimal personal protective eq

44 eated nets, residual spraying of houses, and chemoprophylaxis) and pregnancy (chloroquine chemoprophy

45 el and malaria prevention, long-term malaria chemoprophylaxis, and insect repellent and malaria.

46 among surgical patients who did not receive chemoprophylaxis, and patients at increased levels of Ca

47 Screening, chemoprophylaxis, and vaccination are all effective stra

48 ment of anti-malarial vaccine candidates and chemoprophylaxis approaches that aim to prevent clinical

49 ents and several different strategies of CMV chemoprophylaxis are in practice.

50 Approaches to diagnosis, treatment, and chemoprophylaxis are now in use on the basis of these ad

51 is prevention, even when completion rates of chemoprophylaxis are suboptimal.

52 at might receive extended-duration influenza chemoprophylaxis are unknown.

53 Antimicrobial chemoprophylaxis at time of departure and oral cholera v

54 Antiretroviral chemoprophylaxis before exposure is a promising approach

55 Chemoprophylaxis beginning 1 wk before departure confers

56 estimated glomerular filtration rate in the chemoprophylaxis cohort, 16.0 +/- 3.4 vs. 30.1 +/- 4.7 m

57 icance after adjusting for disease severity, chemoprophylaxis, drug resistance, and social determinan

58 Health authorities vary in the chemoprophylaxis drugs they recommend, the indications f

59 seriousness of malaria, the tolerability of chemoprophylaxis drugs, and the efficacy and safety of r

60 at rates comparable with or lower than other chemoprophylaxis drugs.

61 Disease risk and chemoprophylaxis effectiveness were estimated from publi

62 tility of this HIV-1-based animal model in a chemoprophylaxis experiment, by showing that a commonly

63 test were identified and received isoniazid chemoprophylaxis for 12 months.

64 l spraying (two rounds per year) $32-58; for chemoprophylaxis for children $3-12 (assuming an existin

65 verage to protect vaccinated individuals and chemoprophylaxis for close contacts during outbreaks.

66 rategy of short-term, oral ganciclovir-based chemoprophylaxis for CMV in liver transplant recipients

67 Physicians may need to consider azole chemoprophylaxis for HIV-infected persons who live in ar

68 As a consequence, secondary chemoprophylaxis for leishmaniasis or even the use of an

69 Mefloquine is the drug of choice for chemoprophylaxis for most travelers, with doxycycline an

70 With the success of zidovudine chemoprophylaxis for prevention of perinatal transmissio

71 Rifaximin appears promising as a chemoprophylaxis for travelers' diarrhea and as a treatm

72 should include prophylaxis with antibiotics, chemoprophylaxis for venous thromboembolism, and correct

73 a regarding infections, rejection, infection chemoprophylaxis, graft failure, absolute lymphocyte cou

74 However, patients undergoing VGCV or GCV chemoprophylaxis had more leukocytopenia.

75 weekly clinic visit, but optimum duration of chemoprophylaxis has not been determined.

76 Azithromycin chemoprophylaxis has not been evaluated as a means of li

77 parum-infected mosquitoes during chloroquine chemoprophylaxis (hereafter, chemoprophylaxis and sporoz

78 ntions such as chemotherapy, vaccination and chemoprophylaxis, HIV prevalence, the age structure of t

79 Intrapartum antibiotic chemoprophylaxis (IAP) prevents most early-onset group B

80 ere more likely to receive postdischarge VTE chemoprophylaxis if undergoing rectal cancer surgery [in

81 ent specialists systematically debated about chemoprophylaxis, immunotherapy, immunization, and recom

82 ting the importance of heartworm testing and chemoprophylaxis in all dogs to reduce transmission.

83 prevent recurrent disease, such as lifelong chemoprophylaxis in HIV-1-positive tuberculosis patients

84 reduced cutpoint to determine suitability of chemoprophylaxis in HIV-seropositive persons may be prud

85 n sizes suggest eligibility for tuberculosis chemoprophylaxis in HIV-seropositive than in HIV-seroneg

86 Cases ceased following facility-wide chemoprophylaxis in July 2012.

87 Optimal timing of initiation of isoniazid chemoprophylaxis in liver transplant recipients who test

88 tes without discernible time trends, despite chemoprophylaxis in more than 80% after Year 1, and the

89 Preexposure chemoprophylaxis in only high-risk MSM can improve cost-

90 Studies are needed to evaluate if antiviral chemoprophylaxis in solid organ transplant recipients du

91 sufficient to provide adequate drug for mass chemoprophylaxis in the event of vaccine unavailability.

92 the use of perioperative and in-hospital VTE chemoprophylaxis increased significantly from 31.6% to 8

93 The absolute risk reduction afforded by chemoprophylaxis initiation was 1.1% (95% CI, .6%-1.9%),

94 within 24 hours of diagnosis to ensure that chemoprophylaxis is given to all exposed persons.

95 ancer screening, but illustrate that aspirin chemoprophylaxis is unlikely to be associated with gains

96 e, suggesting that their wide use in topical chemoprophylaxis is unlikely.

97 ed VTE risk stratification helps ensure that chemoprophylaxis is used only in appropriate surgical pa

98 ing itinerary-tailored advice, vaccines, and chemoprophylaxis; it can also help to focus posttravel e

99 Discontinuation of PCP chemoprophylaxis may be appropriate for some HIV-infecte

100 in skilled nursing facilities, facility-wide chemoprophylaxis may be necessary to prevent sustained p

101 Geographically targeted mass chemoprophylaxis might contain the spread of a pandemic

102 ng Pneumocystis isolates and by a control of chemoprophylaxis observance.

103 medications for treatment and post-exposure chemoprophylaxis of human infections with novel influenz

104 Using this model we now show that chemoprophylaxis of latently infected cynomolgus macaque

105 dels for development of additional drugs for chemoprophylaxis of liver injury and emphysema in patien

106 s, it constitutes an excellent candidate for chemoprophylaxis of target organ injury in alpha1-AT def

107 With breast-conserving therapy, chemoprophylaxis or other interventions to reduce the ra

108 participants receiving at least one dose of chemoprophylaxis or placebo were considered for safety,

109 ens, preventing first episodes of disease by chemoprophylaxis or vaccination (primary prophylaxis), a

110 Malaria treatment, chemoprophylaxis, or other forms of parasite suppression

111 ve been preventable with appropriate advice, chemoprophylaxis, or vaccination.

112 other-to-child transmission (MTCT) or failed chemoprophylaxis populates viral reservoirs and limits r

113 led trial showed that daily oral preexposure chemoprophylaxis (PrEP) was effective for HIV prevention

114 Rapid initiation of a chemoprophylaxis program after 2 cases of meningococcal

115 iscussed: awareness of risk, bite avoidance, chemoprophylaxis, rapid diagnosis, stand-by emergency tr

116 10.6% (1399 of 13,230) were discharged on a chemoprophylaxis regimen.

117 Practical and effective chemoprophylaxis regimens for HIV-1-related tuberculosis

118 Assuming full adherence to chemoprophylaxis regimens, consultations saved healthcar

119 re not prevented with the current first-line chemoprophylaxis regimens.

120 ive measures and adhere poorly to continuous chemoprophylaxis regimens.

121 sk areas, and do not appropriately adhere to chemoprophylaxis regimens.

122 inputs were varied over wide ranges, aspirin chemoprophylaxis remained generally non-cost-effective f

123 Extended-duration zanamivir and oseltamivir chemoprophylaxis seems to be highly efficacious for prev

124 tbreaks cannot be predicted, 6 months of PCP chemoprophylaxis should be considered for all RTRs and L

125 Chemoprophylaxis should be restricted to travelers who a

126 of the guidelines for selective intrapartum chemoprophylaxis (SIC) of group B streptococcal early-on

127 tial regimens with different medications for chemoprophylaxis, stand-by emergency self-treatment, and

128 meningitis in the United States despite the chemoprophylaxis strategies for preventing infection rec

129 eningitis in the USA despite CDC-recommended chemoprophylaxis strategies for preventing infection.

130 The initial chemoprophylaxis studies evaluated tenofovir administere

131 cP cases occur in those prescribed effective chemoprophylaxis, suggesting that additional preventive

132 nd-by emergency self-treatment, and seasonal chemoprophylaxis targeting high-incidence periods or loc

133 Guidelines for travellers on malaria chemoprophylaxis, the altitude limits of dominant vector

134 mpare several national guidelines on malaria chemoprophylaxis to identify variations in recommendatio

135 h LTBI that need to be treated with standard chemoprophylaxis to prevent 1 active case.

136 nt tuberculosis infection (LTBI) are offered chemoprophylaxis to prevent active disease; however, the

137 ic analyses have examined the use of aspirin chemoprophylaxis to prevent colorectal cancer either alo

138 Failure to take or adhere to recommended chemoprophylaxis, to promptly seek medical care for post

139 ecember 2006 using the search terms malaria, chemoprophylaxis, travel, mefloquine, neuropsychiatric a

140 Three different treatments-chemoprophylaxis, treatment after exposure but before sy

141 e Preexposure Prophylaxis Initiative (iPrEx) chemoprophylaxis trial provided an opportunity to rigoro

142 r infection after transplantation, isoniazid chemoprophylaxis used during candidacy was well tolerate

143 lunteers taking chloroquine for antimalarial chemoprophylaxis (vaccine approach denoted as PfSPZ-CVac

144 reas who receive concurrent vaccinations and chemoprophylaxis warrant further study.

145 Chemoprophylaxis was administered in 87.0% of the women

146 of CMV syndrome or tissue-invasive disease, chemoprophylaxis was associated with a better preservati

147 Antimicrobial chemoprophylaxis was estimated to provide the greatest p

148 The benefit of peri-operative VTE chemoprophylaxis was only found among surgical patients

149 s in Somalia, mefloquine, a drug for malaria chemoprophylaxis, was not approved for use in pregnant w

150 resulting from traveler adherence to malaria chemoprophylaxis were calculated from 2 perspectives: th

151 Different strategies of chemoprophylaxis were compared.

152 ion of perinatal disease through intrapartum chemoprophylaxis were revised in 2002.

153 In patients who had received chemoprophylaxis with (val-)ganciclovir (n = 63), the CM

154 Chemoprophylaxis with NAIs decreased the frequency of sy

155 Additionally, the efficacy of primary chemoprophylaxis with oral or topical antiretroviral reg

156 tion of healthy volunteers during receipt of chemoprophylaxis with Plasmodium falciparum sporozoites

157 Volunteers immunized under chloroquine chemoprophylaxis with Plasmodium falciparum sporozoites

158 volunteers taking chloroquine or mefloquine (chemoprophylaxis with sporozoites).

159 = 242) and assessed the impact of antiviral chemoprophylaxis with valganciclovir (VGCV) or ganciclov

160 While antiviral chemoprophylaxis with VGCV or GCV in patients with a hig

161 Antiviral chemoprophylaxis with VGCV or GCV in recipients with a h

162 of indirect evidence strongly suggests that chemoprophylaxis with zidovudine after exposure to HIV m